糖尿病合并Stanford B型主动脉夹层患者胸主动脉腔内修复术后30天结局:基于ACS-NSQIP数据库的倾向性评分匹配研究
基于ACS-NSQIP数据库2005至2022年因Stanford B型主动脉夹层行胸主动脉腔内修复术的患者,按1:4倾向性评分匹配比较糖尿病与非糖尿病患者的30天结局。匹配后糖尿病组死亡率有升高趋势但未达统计学显著(10.19% vs 5.89%,p=0.07),所有30天并发症两组相当。作者认为胸主动脉腔内修复术对糖尿病患者短期总体安全,但围术期死亡率可能升高需谨慎考量。
要点
- 匹配后糖尿病组30天死亡率为10.19%,非糖尿病组为5.89%,差异未达统计学显著(p=0.07)。
- 匹配后糖尿病与非糖尿病患者的全部30天并发症相当。
- 作者认为胸主动脉腔内修复术对糖尿病患者短期总体安全,但围术期死亡率可能升高需谨慎考量。
核心结论
- 就短期结局而言,胸主动脉腔内修复术对糖尿病患者总体安全,但这些患者围术期死亡率可能升高,需谨慎考量。
- 作者认为可能需要进一步大规模研究以全面了解糖尿病对胸主动脉腔内修复术后短期和长期结局的影响。
研究设计与样本
- 从美国外科医师学会国家手术质量改进计划(ACS-NSQIP)数据库2005至2022年选取因Stanford B型主动脉夹层行胸主动脉腔内修复术的患者。
- 采用1:4倾向性评分匹配平衡糖尿病与非糖尿病组的人口学与术前特征,比较30天术后结局。
- 共160例(8.89%)糖尿病患者和1640例(91.11%)非糖尿病患者;匹配后全部糖尿病患者与594例非糖尿病患者匹配。
主要发现
- 匹配后糖尿病组死亡率有升高趋势但未达统计学显著:糖尿病组10.19% vs 非糖尿病组5.89%,p=0.07。
- 匹配后糖尿病组与非糖尿病组的所有30天并发症相当。
临床怎么用
- 作者认为胸主动脉腔内修复术对糖尿病患者短期总体安全,但围术期死亡率可能升高需谨慎考量。
- 原文未据此给出具体推荐。
局限性
- 原文指出糖尿病患者围术期死亡率可能升高需谨慎考量。
- 原文结论称可能需要进一步大规模研究以全面了解糖尿病对胸主动脉腔内修复术后短期和长期结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The surgical intervention for Stanford type B aortic dissection (TBAD) has been revolutionized by thoracic endovascular aortic repair (TEVAR). While diabetes mellitus (DM) is associated with increased risks of short-term mortality and infectious complications after major surgeries, previous studies present conflicting findings regarding the outcomes of TEVAR in DM patients. This study aimed to assess the 30-day postoperative outcomes for DM patients who have undergone TEVAR for TBAD using a dataset from a multi-institutional national registry. METHODS: Patients who underwent TEVAR for TBAD were selected from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database from 2005 to 2022. A 1:4 propensity-score matching was used to balance demographics and preoperative characteristics between patients with and without DM. Thirty-day postoperative outcomes were compared. RESULTS: There were 160 (8.89%) DM and 1640 (91.11%) non-DM patients who underwent TEVAR for TBAD. After propensity-score matching, all DM patients were matched to 594 non-DM patients. DM patients had a higher rate of mortality that was trending toward significance (10.19% vs 5.89%, p = 0.07). All 30-day complications were comparable between DM and non-DM patients. CONCLUSION: TEVAR can generally be safe for DM patients in terms of short-term outcomes, but the potential for higher perioperative mortality rates in these patients may warrant careful consideration. Further large-scale studies may be necessary to fully understand the impact of DM on both short-term and long-term outcomes following TEVAR for TBAD.Clinical ImpactThis study assessed the 30-day postoperative outcomes for diabetes mellitus (DM) patients who have undergone thoracic endovascular aortic repair (TEVAR) for Stanford type B aortic dissection (TBAD) using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. After propensity-score matching, DM patients had a higher rate of mortality that was trending toward significance but all 30-day complications were comparable between DM and non-DM patients. Therefore, TEVAR can generally be safe for DM patients in terms of short-term outcomes, but the potential for higher perioperative mortality rates in these patients may warrant careful consideration. Further large-scale studies may be necessary to fully understand the impact of DM on both short-term and long-term outcomes following TEVAR for TBAD.
引用
- Li R, Sidawy A, Nguyen BN, et al. Thirty-Day Endovascular Repair Outcomes of Stanford Type B Aortic Dissection in Patients With Diabetes Mellitus: A Propensity-Score-Matched Study From the ACS-NSQIP Database. J Endovasc Ther. 2025. PMID: 40079407. doi:10.1177/15266028251324823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。